The recent flurry of development activity focused on NASH holds great promise for much needed diagnostics and treatment options, however, commercial success is far from a foregone conclusion. This whitepaper explores future treatment for NASH and a number of major challenges to overcome.
Non-alcoholic Steatohepatitis (NASH) is a condition characterised by excessive fat deposits in the liver, accompanied by inflammation and liver cell damage. In addition, NASH has been associated with increased cardiovascular events independent of its risk factors of type 2 diabetes, obesity and hypertriglyceridemia.
NASH is a complex disease, with poorly understood pathogenesis and natural history of disease, while significant unmet medical needs exist, both for reliable, non-invasive diagnostic procedures as well as effective treatments.
IQVIA is using vast quantities of data in powerful new ways. See how we can help you tap into information from past trials, patient reported outcomes and other sources to accelerate your research.
Richer real world data insights can drive smarter decisions.
Ensure your stakeholders are getting the information they need, when and where they need it, to see where your product can improve outcomes.
